Lilly Weight-Loss Drug Keeps Patients Diabetes-Free

Published on November 14, 2024

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide – the active ingredient in Lilly’s diabetes drug Mounjaro and weight-loss treatment Zepbound -…

Read Full Article (External Site)